Multiple clinical studies have demonstrated that IGF1-negative patients with CRC in KRAS-WT treated with irinotecan-cetuximab have higher responses, higher median-PFS and higher median-OS than IGF1-positive patients [172,175]. The gene discussed is KRAS; the disease is colorectal carcinoma.